Induction of a protective immunity against Schistosoma mansoni with ovalbumin-coupled Sm37-5 coadsorbed with granulocyte-macrophage colony stimulating factor (GM-CSF) or IL-12 on alum

Vaccine

Volumn 17, Issue 1, 1999, Pages 13-18

  Argiro, Laurent ^a   Henri, Sandrine ^a   Dessein, Hélia ^a   Dessein, Alain J ^a   Bourgois, A ^a  

^a Aix Marseille university   (France)

Author keywords

Cytokine; Schistosomiasis; Vaccination

Indexed keywords

ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 12; OVALBUMIN; SM 37 5; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PARASITE IDENTIFICATION; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS;

ADJUVANTS, IMMUNOLOGIC; ADSORPTION; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; EPITOPES, B-LYMPHOCYTE; FEMALE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNITY, NATURAL; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-12; MICE; MICE, INBRED CBA; MOLECULAR WEIGHT; OVALBUMIN; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI;

EID: 0032889084     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00152-2     Document Type: Article

References (23)

1. Goudot-Crozel V, Caillol D, Djabali M, Dessein A.J. The major parasite surface antigen associated with human resistance to schistosomiasis is a 37-kDa glyceraldehyde-3-phosphate dehydrogenase. J Exp Med. 170:1989;2063-2080.
2. Dessein A.J., Begley M, Demeure C, Caillol D, Fueri J, Dos Reis M.G., Andrade Z.A., Prata A, Bina J.C. Human resistance to Schistosoma mansoni is associated with IgG reactivity to a 37-kDa larval surface antigen. J Immunol. 140:1988;2727-2736.
3. Wright M.D., Daven K.M., Mitchell G.F. The functional and immunological significance of some schistosome surface molecules. Parasitol Today. 7:1991;56-58.
4. Bergquist N.R. Controlling schistosomiasis by vaccination: a realistic option? Parasitol Today. 5:1995;191-194.
5. Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol. 13:1995;399-415.
6. Ada G, Ramsay A. Vaccines, vaccination and the immune response. Philadelphia: Lippincott-Raven Ed., 1997.
7. Burgess A.W., Camakaris J, Metcalf D Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J Biol Chem. 252:1977;1998-2003.
8. Morrissey P.J., Bressler L, Park L.S., Alpert A, Gillis S Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol. 139:1987;1113-1119.
9. Heufler C, Koch F, Schuler G Granulocyte/macrophage colony-stimulating factor and interleukin-1 mediate the maturation of murine epidermal langerhans cells into potent immunostimulatory dendritic cells. J Exp Med. 167:1988;700-705.
10. Fischer H.-G., Frosch S, Reske K, Reske-Kunz A.B. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol. 141:1988;3882-3888.
11. Smith P.D., Lamerson C.L., Wong H.L., Wahl LM, Wahl S.M. Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. J Immunol. 144:1990;3829-3834.
12. Tao M-H, Levy R Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B cell lymphoma. Nature. 362:1993;755-758.
13. Chen T.T., Tao M-H, Levy R Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4 and granulocyte-macrophage colony-stimulating factor. J Immunol. 153:1994;4775-4786.
14. Tarr P.E., Lin R, Mueller E.A., Kovarik J.M., Guillaume M, Jones T.C. Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine. 14:1996;1199-1204.
15. Scott P IL-12: initiation cytokine for cell-mediated immunity. Science. 260:1993;496-497.
16. Germann T, Bongartz M, Dlugonska H, Hess H, Schmitt E, Kolbe L, Kölsch E, Podlaski F.J., Gately M.K., Rüde E Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol. 25:1995;823-829.
17. Afonso L.C.C., Scharton T.M., Vieira L.Q., Wysocka M, Trinchieri G, Scott P The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 263:1994;235-237.
18. Wynn T.A., Cheever A.W., Jankovic D, Poindexter R.W., Caspar P, Lewis F.A., Sher A An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature. 376:1995;594-596.
19. Smithers S.R., Terry R.J. The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms. Parasitology. 55:1965;695-700.
20. Rihet P, Demeure C.E., Dessein A.J., Bourgois A Strong serum inhibition of specific IgE correlated to competing IgG4, revealed by a new methodology in subjects from a S. mansoni endemic area. Eur J Immunol. 22:1992;2063-2070.
21. Metzger D.W., McNutt R.M., Collins J.T., Buchanan J.M., Van Cleave V.H.V., Dunnick W.A. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-γ-dependant and independant mechanisms. Eur J Immunol. 27:1997;1958-1965.
22. Bliss J, Van Cleave V, Murray K, Wiencis A, Ketchum M, Maylor R, Haire T, Resmini C, Abbas A.K., Wolf S.F. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol. 156:1996;887-894.
23. TDR-coordinated laboratory Schistosomiasis vaccines: human correlate studies pave the way. TDR News. 54:1997;4.